Does the media refer more to PRGO or ASMB?

In the previous week, Perrigo and Perrigo both had 4 articles in the media. Assembly Biosciences' average media sentiment score of 1.22 beat Perrigo's score of 1.14 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASMB or PCRX?

In the previous week, Pacira BioSciences had 5 more articles in the media than Assembly Biosciences. MarketBeat recorded 9 mentions for Pacira BioSciences and 4 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 1.22 beat Pacira BioSciences' score of 0.72 indicating that Assembly Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to OMER or ASMB?

In the previous week, Omeros had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 5 mentions for Omeros and 4 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 1.22 beat Omeros' score of 0.55 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CPIX or ASMB?

Assembly Biosciences has a consensus target price of $44.00, indicating a potential upside of 76.81%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Assembly Biosciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media refer more to CPIX or ASMB?

In the previous week, Assembly Biosciences had 1 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 4 mentions for Assembly Biosciences and 3 mentions for Cumberland Pharmaceuticals. Assembly Biosciences' average media sentiment score of 1.22 beat Cumberland Pharmaceuticals' score of 0.52 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LLY or ASMB?

In the previous week, Eli Lilly and Company had 113 more articles in the media than Assembly Biosciences. MarketBeat recorded 117 mentions for Eli Lilly and Company and 4 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 1.22 beat Eli Lilly and Company's score of 0.71 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eli Lilly and Company 68 Very Positive mention(s) 14 Positive mention(s) 22 Neutral mention(s) 9 Negative mention(s) 3 Very Negative mention(s) Positive Assembly Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Assembly Biosciences (ASMB) Competitors

$24.88 -0.69 (-2.68%)

As of 12:19 PM Eastern

Compare

ASMB vs. PRGO, PCRX, OMER, CPIX, and LLY

Should you buy Assembly Biosciences stock or one of its competitors? MarketBeat compares Assembly Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Assembly Biosciences include Perrigo (PRGO), Pacira BioSciences (PCRX), Omeros (OMER), Cumberland Pharmaceuticals (CPIX), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceuticals" industry.

How does Assembly Biosciences compare to Perrigo?

Perrigo (NYSE:PRGO) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Perrigo and Perrigo both had 4 articles in the media. Assembly Biosciences' average media sentiment score of 1.22 beat Perrigo's score of 1.14 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assembly Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Perrigo currently has a consensus target price of $19.33, suggesting a potential upside of 84.92%. Assembly Biosciences has a consensus target price of $44.00, suggesting a potential upside of 76.81%. Given Perrigo's higher possible upside, equities research analysts plainly believe Perrigo is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Assembly Biosciences has lower revenue, but higher earnings than Perrigo. Assembly Biosciences is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.34	-$1.43B	-$13.10	N/A
Assembly Biosciences	$71.10M	5.56	-$6.12M	-$0.11	N/A

95.9% of Perrigo shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 0.4% of Perrigo shares are held by insiders. Comparatively, 3.5% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Assembly Biosciences has a net margin of -8.98% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Perrigo has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Summary

Assembly Biosciences beats Perrigo on 9 of the 15 factors compared between the two stocks.

How does Assembly Biosciences compare to Pacira BioSciences?

Assembly Biosciences (NASDAQ:ASMB) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Pacira BioSciences has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$71.10M	5.56	-$6.12M	-$0.11	N/A
Pacira BioSciences	$726.41M	1.44	$7.03M	$0.12	220.83

Pacira BioSciences has a net margin of 0.70% compared to Assembly Biosciences' net margin of -8.98%. Pacira BioSciences' return on equity of 10.24% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Pacira BioSciences	0.70%	10.24%	5.47%

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Assembly Biosciences presently has a consensus price target of $44.00, indicating a potential upside of 76.81%. Pacira BioSciences has a consensus price target of $29.40, indicating a potential upside of 10.94%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Pacira BioSciences had 5 more articles in the media than Assembly Biosciences. MarketBeat recorded 9 mentions for Pacira BioSciences and 4 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 1.22 beat Pacira BioSciences' score of 0.72 indicating that Assembly Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Assembly Biosciences has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Summary

Pacira BioSciences beats Assembly Biosciences on 10 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Omeros?

Omeros (NASDAQ:OMER) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Omeros has a beta of 2.55, indicating that its stock price is 155% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -8.98%. Assembly Biosciences' return on equity of -4.21% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Omeros presently has a consensus price target of $38.00, indicating a potential upside of 230.46%. Assembly Biosciences has a consensus price target of $44.00, indicating a potential upside of 76.81%. Given Omeros' higher probable upside, research analysts clearly believe Omeros is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Omeros had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 5 mentions for Omeros and 4 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 1.22 beat Omeros' score of 0.55 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assembly Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros has higher earnings, but lower revenue than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	16.43
Assembly Biosciences	$71.10M	5.56	-$6.12M	-$0.11	N/A

48.8% of Omeros shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 3.5% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Omeros beats Assembly Biosciences on 11 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Cumberland Pharmaceuticals has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Assembly Biosciences has a net margin of -8.98% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Assembly Biosciences' return on equity of -4.21% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Assembly Biosciences has a consensus target price of $44.00, indicating a potential upside of 76.81%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Assembly Biosciences had 1 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 4 mentions for Assembly Biosciences and 3 mentions for Cumberland Pharmaceuticals. Assembly Biosciences' average media sentiment score of 1.22 beat Cumberland Pharmaceuticals' score of 0.52 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assembly Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cumberland Pharmaceuticals has higher earnings, but lower revenue than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$41.94M	2.35	-$2.84M	-$0.49	N/A
Assembly Biosciences	$71.10M	5.56	-$6.12M	-$0.11	N/A

Summary

Assembly Biosciences beats Cumberland Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Eli Lilly and Company?

Eli Lilly and Company (NYSE:LLY) and Assembly Biosciences (NASDAQ:ASMB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Eli Lilly and Company currently has a consensus target price of $1,283.64, indicating a potential upside of 5.44%. Assembly Biosciences has a consensus target price of $44.00, indicating a potential upside of 76.81%. Given Assembly Biosciences' higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	2 Strong Buy rating(s)	2.87
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Eli Lilly and Company has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$72.25B	15.87	$20.64B	$28.15	43.25
Assembly Biosciences	$71.10M	5.56	-$6.12M	-$0.11	N/A

Eli Lilly and Company has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by insiders. Comparatively, 3.5% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Eli Lilly and Company has a net margin of 34.98% compared to Assembly Biosciences' net margin of -8.98%. Eli Lilly and Company's return on equity of 105.77% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	34.98%	105.77%	23.76%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

In the previous week, Eli Lilly and Company had 113 more articles in the media than Assembly Biosciences. MarketBeat recorded 117 mentions for Eli Lilly and Company and 4 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 1.22 beat Eli Lilly and Company's score of 0.71 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	68 Very Positive mention(s)	14 Positive mention(s)	22 Neutral mention(s)	9 Negative mention(s)	3 Very Negative mention(s)	Positive
Assembly Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Eli Lilly and Company beats Assembly Biosciences on 13 of the 17 factors compared between the two stocks.

Get Assembly Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASMB vs. The Competition

Export

Metric	Assembly Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$395.99M	$6.54B	$7.06B	$12.00B
Dividend Yield	N/A	0.68%	2.66%	8.55%
P/E Ratio	-226.49	10.85	27.34	23.55
Price / Sales	5.56	21.78	578.45	106.50
Price / Cash	N/A	7.96	49.60	59.05
Price / Book	1.91	4.17	10.00	6.00
Net Income	-$6.12M	$99.67M	$3.60B	$336.19M
7 Day Performance	-4.44%	0.33%	-1.55%	-2.39%
1 Month Performance	-7.70%	-4.05%	-4.19%	-5.42%
1 Year Performance	35.54%	94.09%	19.52%	13.30%

Assembly Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASMB Assembly Biosciences	2.8244 of 5 stars	$24.89 -2.7%	$44.00 +76.8%	+31.1%	$395.99M	$71.10M	N/A	100	News Coverage Positive News Upcoming Earnings
PRGO Perrigo	4.3725 of 5 stars	$10.10 -3.5%	$19.33 +91.3%	-63.5%	$1.40B	$4.25B	N/A	8,100	News Coverage Positive News Upcoming Earnings
PCRX Pacira BioSciences	1.9576 of 5 stars	$25.93 +1.3%	$29.40 +13.4%	+21.6%	$1.02B	$726.41M	216.10	720	News Coverage Upcoming Earnings
OMER Omeros	3.2655 of 5 stars	$10.30 +4.7%	$38.00 +268.9%	+171.8%	$745.51M	N/A	14.71	210	Analyst Forecast
CPIX Cumberland Pharmaceuticals	0.4872 of 5 stars	$6.98 -1.8%	N/A	+95.7%	$104.56M	$44.52M	N/A	80	News Coverage Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASMB) was last updated on 7/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assembly Biosciences (ASMB) Competitors

ASMB vs. PRGO, PCRX, OMER, CPIX, and LLY

How does Assembly Biosciences compare to Perrigo?

Summary

How does Assembly Biosciences compare to Pacira BioSciences?

Summary

How does Assembly Biosciences compare to Omeros?

Summary

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Summary

How does Assembly Biosciences compare to Eli Lilly and Company?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Assembly Biosciences (ASMB) Competitors

ASMB vs. PRGO, PCRX, OMER, CPIX, and LLY

How does Assembly Biosciences compare to Perrigo?

Does the media refer more to PRGO or ASMB?

Do analysts recommend PRGO or ASMB?

Which has preferable earnings and valuation, PRGO or ASMB?

Do insiders and institutionals hold more shares of PRGO or ASMB?

Is PRGO or ASMB more profitable?

Which has more volatility & risk, PRGO or ASMB?

Summary

How does Assembly Biosciences compare to Pacira BioSciences?

Which has higher earnings & valuation, ASMB or PCRX?

Is ASMB or PCRX more profitable?

Do insiders & institutionals believe in ASMB or PCRX?

Do analysts prefer ASMB or PCRX?

Does the media prefer ASMB or PCRX?

Which has more volatility & risk, ASMB or PCRX?

Summary

How does Assembly Biosciences compare to Omeros?

Which has more risk and volatility, OMER or ASMB?

Is OMER or ASMB more profitable?

Do analysts rate OMER or ASMB?

Does the media refer more to OMER or ASMB?

Which has better valuation & earnings, OMER or ASMB?

Do insiders and institutionals believe in OMER or ASMB?

Summary

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Which has more volatility and risk, CPIX or ASMB?

Do insiders and institutionals believe in CPIX or ASMB?

Is CPIX or ASMB more profitable?

Do analysts prefer CPIX or ASMB?

Does the media refer more to CPIX or ASMB?

Which has higher earnings & valuation, CPIX or ASMB?

Summary

How does Assembly Biosciences compare to Eli Lilly and Company?

Do analysts recommend LLY or ASMB?

Which has preferable valuation & earnings, LLY or ASMB?

Which has more risk & volatility, LLY or ASMB?

Do insiders & institutionals have more ownership in LLY or ASMB?

Is LLY or ASMB more profitable?

Does the media refer more to LLY or ASMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools